Amgen, Inc. (NASDAQ:AMGN) Stock Holdings Boosted by M&R Capital Management Inc.

M&R Capital Management Inc. raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,910 shares of the medical research company’s stock after purchasing an additional 95 shares during the quarter. M&R Capital Management Inc.’s holdings in Amgen were worth $739,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AMGN. Price Wealth LLC grew its stake in Amgen by 42.9% during the 2nd quarter. Price Wealth LLC now owns 140 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 42 shares in the last quarter. Lake Point Wealth Management grew its stake in Amgen by 1,590.0% during the 1st quarter. Lake Point Wealth Management now owns 169 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 159 shares in the last quarter. Campbell Wealth Management purchased a new position in Amgen during the 2nd quarter valued at about $51,000. Demars Financial Group LLC bought a new stake in shares of Amgen in the 2nd quarter valued at approximately $53,000. Finally, 1776 Wealth LLC bought a new stake in shares of Amgen in the 2nd quarter valued at approximately $59,000. Institutional investors own 75.23% of the company’s stock.

Several brokerages recently commented on AMGN. Royal Bank of Canada lowered their price target on Amgen from $236.00 to $223.00 and set a “sector perform” rating for the company in a research note on Wednesday, July 29th. SVB Leerink boosted their price target on Amgen from $253.00 to $261.00 and gave the company a “market perform” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a research note on Tuesday, September 22nd. ValuEngine raised Amgen from a “sell” rating to a “hold” rating in a research note on Tuesday, September 1st. Finally, William Blair restated a “hold” rating on shares of Amgen in a report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $255.16.

In other Amgen news, Director R Sanders Williams sold 250 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $242.95, for a total value of $60,737.50. Following the transaction, the director now directly owns 5,159 shares in the company, valued at $1,253,379.05. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $241.02, for a total transaction of $241,020.00. In the last ninety days, insiders sold 2,250 shares of company stock worth $561,548. 0.36% of the stock is owned by insiders.

Shares of NASDAQ AMGN traded up $1.23 during trading hours on Thursday, reaching $255.39. The stock had a trading volume of 2,271,401 shares, compared to its average volume of 2,886,134. The business’s fifty day moving average is $244.99 and its two-hundred day moving average is $233.95. The company has a debt-to-equity ratio of 3.20, a current ratio of 2.18 and a quick ratio of 1.81. The company has a market cap of $149.58 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 2.15 and a beta of 0.85. Amgen, Inc. has a twelve month low of $177.05 and a twelve month high of $264.97.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 28th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.81 by $0.44. The business had revenue of $6.21 billion during the quarter, compared to analyst estimates of $6.19 billion. Amgen had a return on equity of 91.98% and a net margin of 30.04%. Amgen’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $3.97 earnings per share. Sell-side analysts forecast that Amgen, Inc. will post 15.64 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Monday, August 17th were paid a $1.60 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $6.40 annualized dividend and a dividend yield of 2.51%. Amgen’s dividend payout ratio is presently 43.18%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.